GW-501516 (Cardarine): PPARδ Agonism, Skeletal Muscle Metabolic Reprogramming, and Fatty Acid Oxidation in Research Models

Abstract & Overview GW-501516 — also designated GW1516, GSK-516, Cardarine, and Endurobol — is a synthetic, orally bioavailable small-molecule agonist of the peroxisome proliferator-activated receptor delta (PPARδ), a ligand-activated nuclear transcription factor that serves as a master regulator of fatty acid catabolism, mitochondrial biogenesis, and skeletal muscle fibre-type programming. Developed through a collaborative research programme between GlaxoSmithKline and Ligand Pharmaceuticals beginning in 1992, GW-501516 was initially investigated as a therapeutic candidate for metabolic syndrome, dyslipidaemia, obesity, and cardiovascular disease [1][2]. The compound displays exceptional receptor selectivity — binding PPARδ with a Ki and EC50 of approximately 1 nM and exhibiting greater than 1,000-fold selectivity over the closely related PPARα and PPARγ subtypes [1]. Preclinical studies demonstrated that GW-501516 shifts skeletal muscle energy substrate utilisation from glucose to fatty acids, increases the proportion of oxidative slow-twitch muscle fibres, enhances running endurance, improves the lipid profile, and protects against diet-induced obesity and type II diabetes in rodent and primate models [3][4][5]. These properties led to its characterisation as an ‘exercise mimetic’ — a compound capable of pharmacologically replicating certain molecular adaptations of endurance training [4]. “PPARβ/δ agonist and exercise training synergistically increase oxidative myofibers and running endurance in adult mice… AMPK-PPARδ pathway can be targeted by orally active drugs to enhance training adaptation or even to increase endurance without exercise.” — Narkar VA et al., Cell (2008) [4]. Despite this compelling preclinical profile, GW-501516 was discontinued by GSK in 2007 following the emergence of carcinogenicity data in animal studies, which demonstrated rapid tumour development across multiple organ systems at research doses. The compound has since been added to the World Anti-Doping Agency (WADA) prohibited list and has never received regulatory approval for human use. It remains an important research tool for elucidating PPARδ biology and the molecular basis of exercise adaptation [6][7]. Molecular Identity and Structural Architecture GW-501516 is a small-molecule synthetic compound with the molecular formula C₂₁H₁₈F₃NO₃S₂ and a molar mass of 453.49 g/mol (CAS: 317318-70-0; PubChem CID: 9803963; DrugBank: DB05416). Its IUPAC name is {4-[({4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl}methyl)sulfanyl]-2-methylphenoxy}acetic acid. The molecule is administered orally and was developed using combinatorial chemistry and structure-based drug design approaches, as reported by Oliver et al. in PNAS (2001) [1]. The structural architecture of GW-501516 comprises four key pharmacophoric elements: a 4-(trifluoromethyl)phenyl group that anchors the molecule within the PPARδ ligand-binding domain; a 4-methyl-1,3-thiazol-5-yl heterocyclic core that provides the scaffold for receptor engagement; a thioether (methylsulfanyl) linker connecting the thiazole to the phenoxy moiety; and a 2-methylphenoxyacetic acid terminus that contributes to binding affinity and metabolic stability. The trifluoromethyl group is particularly important for selectivity, as it creates hydrophobic contacts within the PPARδ binding pocket that are not accommodated by PPARα or PPARγ [1][2]. The compound’s selectivity profile is exceptional: Ki = 1 nM and EC50 = 1 nM for PPARδ, with greater than 1,000-fold selectivity over PPARα and PPARγ. At higher concentrations, some PPARα agonism has been reported, which may contribute to additional lipid-lowering effects via hepatic fatty acid oxidation pathways. GW-501516 is orally bioavailable and has been used extensively as a research tool to dissect the physiological and pathophysiological functions of PPARδ in metabolic disease models [1][2]. Mechanistic Rationale: PPARδ Activation and Downstream Signalling PPARδ Ligand Binding and PGC-1α Coactivator Recruitment Upon oral administration, GW-501516 enters the systemic circulation and gains access to target tissues — principally skeletal muscle, adipose tissue, liver, and the cardiovascular system. Within these tissues, GW-501516 binds to the ligand-binding domain of PPARδ with nanomolar affinity, inducing a conformational change in the receptor that facilitates recruitment of the transcriptional coactivator peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α). The resulting PPARδ/PGC-1α complex translocates to the nucleus and binds to peroxisome proliferator response elements (PPREs) in the promoter regions of target genes, initiating a coordinated transcriptional programme centred on fatty acid catabolism and mitochondrial biogenesis [3][4]. Key transcriptional targets of the GW-501516-activated PPARδ/PGC-1α complex include: carnitine palmitoyltransferase 1 (CPT1), the rate-limiting enzyme for mitochondrial fatty acid imp

For research use only. Not for human consumption.